Home health remedies Pfizer plans to farm out sterile injectable manufacturing to make way for...

Pfizer plans to farm out sterile injectable manufacturing to make way for COVID-19 vaccine

8
0
SHARE

Pfizer has dedicated enormous resources to churning out hundreds of millions of doses of a possible COVID-19 vaccine. But that massive effort requires a trade-off: Pfizer will have a hard time meeting production goals for its existing meds and will look to its contractor network to help keep up. 

Pfizer plans to outsource production of some of its drug portfolio to make way for a rapidly growing vaccine manufacturing effort, the company said Monday.

The drugmaker will lean on its 200-strong network of contractors as part of a plan to “build a robust U.S.-based supply chain as well as one based in Europe,” a Pfizer spokesperson said.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

Pfizer said it came to the outsourcing decision after determining that its COVID-19 shot rollout would heavily tax its ability to produce 1.5 billion doses of sterile injectables each year. 

“We determined that producing the volume of doses that we have committed to, in addition to our existing medicines and vaccines, will make significant demands on our network,” the spokesperson said.

Pfizer’s contracting network includes major players Lonza, Catalent and Thermo Fisher Scientific, among others, Pfizer’s head of global supply Mike McDermott told Reuters last week. The drugmaker didn’t specify which of its contractors would be tapped in the effort, Reuters said.

In parallel with its outsourcing push, Pfizer is also working to build up inventory for its sterile injectables before manufacturing of the potential vaccine launches at scale. 

RELATED: Pfizer tags 3 U.S. manufacturing sites for possible COVID-19 vaccine launch

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

sixteen − 6 =